{
  "id": 6478918,
  "title": "Acumen at Cantor Fitzgerald conference: sabirnetug, brain-shuttle push",
  "url": "https://urgent.news/2026/09/09/acumen-at-cantor-fitzgerald-conference-sabirnetug-brain-shuttle-push",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-09T21:15:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/acumen-at-cantor-fitzgerald-conference-sabirnetug-brainshuttle-push-93CH-4894612"
  },
  "original_language": "en",
  "account": "At the 12th Annual Cantor Fitzgerald Global Healthcare Conference, Acumen Pharmaceuticals (ABOS) argued that its experimental drug sabirnetug offers a unique approach for treating Alzheimer's disease. Unlike currently approved amyloid-lowering therapies that target plaques, sabirnetug aims to reduce toxic amyloid beta oligomers, which the company believes could preserve synaptic function and yield faster cognitive benefits.\n\nPhase I data from Acumen's INTERCEPT-AD study showed remarkable selectivity for oligomers (10,000-fold versus monomers) and promising biomarker changes. However, the company emphasized that the pivotal Phase II ALTITUDE-AD trial, enrolling 542 patients, will provide definitive results expected in Q4 2024. Management noted that a 30% or greater slowing in cognitive decline, along with competitive safety, would constitute a clear win.\n\nStrategically, Acumen's focus on oligomers differentiates its program from existing therapies like lecanemab and donanemab, which target plaques. The company sees this as a distinct value proposition for both patients and physicians. While the near-term focus is on the positive Phase II readout, Acumen believes that demonstrating efficacy and biology through successful Phase II results could reshape perspectives on amyloid-directed treatments.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Harrow at Cantor healthcare conference: long view, bigger eye-care bet",
        "url": "https://urgent.news/2026/09/09/harrow-at-cantor-healthcare-conference-long-view-bigger-eye-care-bet",
        "published": "2026-09-09T19:25:44.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}